Silence Therapeutics Plc (SLN.L) said it has signed an agreement with MiReven Pty Ltd. to assess the delivery potential of Silence Therapeutics' proprietary delivery systems with MiReven's novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research on the anti-cancer potential of miR-7.
As per the terms of the agreement, Silence Therapeutics will formulate a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems in order to assess miR-7 in various cancer models. The company will undertake in vitro and in vivo studies of the formulated miR-7. Silence Therapeutics is being paid an undisclosed fee for the collaboration.
For comments and feedback: editorial@rttnews.com